Craft

Bio-Rad

Stock Price

$331.6

2024-10-29

Market Capitalization

$9.2 B

2024-10-29

Revenue

$2.6 B

FY, 2024

Bio-Rad Summary

Company Summary

Overview
Bio-Rad Laboratories is a company that develops, manufactures, and sells life science research and clinical diagnostics products. It operates in two segments: Life Science and Clinical Diagnostics. The Life Science segment offers instruments, systems, reagents, and consumables used to separate, purify, characterize, and quantify biological materials. The Clinical Diagnostics segment provides test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories.
Type
Public
Status
Active
Founded
1952
HQ
Hercules, CA, US | view all locations
Website
https://www.bio-rad.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Norman Schwartz

    Norman Schwartz, Chairman of the Board, President and Chief Executive Officer

    • Andrew Last

      Andrew Last, Executive Vice President, Chief Operating Officer

    • Ilan Daskal

      Ilan Daskal, Executive Vice President, Chief Financial Officer

    • Ajit Ramalingam

      Ajit Ramalingam, Senior Vice President, Chief Accounting Officer

    Operating MetricsView all

    Products

    12K

    Q1, 2023

    Clinical Diagnostic Tests Covered

    300

    FY, 2022

    Countries

    35

    Q1, 2023

    LocationsView all

    46 locations detected

    • Hercules, CA HQ

      United States

      1000 Alfred Nobel Dr

    • South Granville, NSW

      Australia

      1a/62 Ferndell St

    • South Granville, NSW

      Australia

      3e/62 Ferndell St

    • Wien, Wien

      Austria

      Am Europl. 2

    • Lokeren, Vlaams Gewest

      Belgium

      Dieptestraat 2

    • Temse, Vlaams Gewest

      Belgium

      Winninglaan 3

    and 40 others

    Bio-Rad Financials

    Summary Financials

    Revenue (Q1, 2025)
    $585.4M
    Gross profit (Q1, 2025)
    $306.0M
    Net income (Q1, 2025)
    $64.0M
    Cash (Q1, 2025)
    $521.4M
    EBIT (Q1, 2025)
    $23.7M
    Enterprise value
    $8.8B

    Footer menu